Spero Therapeutics Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Spero Therapeutics stock.
View analyst ratings for Spero Therapeutics or view top-rated stocks.

Wall Street analysts have given Spero Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Spero Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Spero Therapeutics.

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its quarterly earnings results on Thursday, August, 5th. The company reported ($0.63) EPS for the quarter, beating the Zacks' consensus estimate of ($0.77) by $0.14. Spero Therapeutics had a negative net margin of 411.53% and a negative trailing twelve-month return on equity of 63.74%.
View Spero Therapeutics' earnings history.

4 brokers have issued twelve-month price targets for Spero Therapeutics' shares. Their forecasts range from $19.00 to $70.00. On average, they anticipate Spero Therapeutics' share price to reach $44.00 in the next year.
View analysts' price targets for Spero Therapeutics or view top-rated stocks among Wall Street analysts.

27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Spero Therapeutics include Ligand Pharmaceuticals (LGND), IGM Biosciences (IGMS), Corcept Therapeutics (CORT), Arcus Biosciences (RCUS), Erasca (ERAS), ATA (ATAI), Rocket Pharmaceuticals (RCKT), Protagonist Therapeutics (PTGX), Nuvation Bio (NUVB), Atea Pharmaceuticals (AVIR), Harmony Biosciences (HRMY), Indivior (INVVY), Myovant Sciences (MYOV), Amarin (AMRN) and Organogenesis (ORGO).
View all of SPRO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Spero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.53%), Vanguard Group Inc. (3.97%), State Street Corp (2.52%), Geode Capital Management LLC (1.29%), Dimensional Fund Advisors LP (1.16%) and Northern Trust Corp (0.81%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends for Spero Therapeutics.

SPRO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Goldman Sachs Group Inc., Morgan Stanley, Morgan Stanley, Citigroup Inc., Rafferty Asset Management LLC, Advisor Group Holdings Inc., and Russell Investments Group Ltd.. Company insiders that have sold Spero Therapeutics company stock in the last year include Ankit Mahadevia, Aquilo Capital Management, Llc, and Cristina Larkin.
View insider buying and selling activity for Spero Therapeutics or view top insider-selling stocks.

SPRO stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC, JPMorgan Chase & Co., Dimensional Fund Advisors LP, Liberty Wealth Management LLC, Wells Fargo & Company MN, Northern Trust Corp, and ProShare Advisors LLC.
View insider buying and selling activity for Spero Therapeutics or or view top insider-buying stocks.

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Spero Therapeutics has a market capitalization of $0.00 and generates $9.33 million in revenue each year. The company earns $-78,280,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

Spero Therapeutics employs 89 workers across the globe.

The official website for Spero Therapeutics is sperotherapeutics.com.

Spero Therapeutics is headquartered at 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139.

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at (857) 242-1600 or via email at [email protected].